YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Novartis Out of RNAi Research

April 15, 2014 | Novartis bows out of RNAi research, the second big pharma to do so. But does that mean RNAi is a dead end technology? Probably not. Alnylam is still heavily invested. Forbes
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.